TABLE 4.

In vitro and in vivo data for small-molecule therapeutics against Ebola^a

Compound (reference)	EC50 (μM)	Drug class	Dose (mg/kg) and dosage regimenb	% survival (treatment) in mice	% survival (control) in mice
Amodiaquine (10)	34†, 2.6*	Antimalarial	60, i.p., BID	0	0
Benztropine (10)	9.2†, 14*	Antihistamine/anticholinergic	13, p.o., QD	10	0
			5, i.p., BID	10	0
Chloroquine (36, 57)	16†, 4.7*	Antimalarial antirheumatic	90, i.p., BID	80	0
			90, i.p., BID	0	0
Chlorotetracycline (10)	24†, >50*	Antibiotic	200, p.o., QD	0	0
			50, i.p., BID	0	0
Clomiphene (10)	11†, 1.3*	Selective estrogen modulator	60, i.p., BID	10	0
			21, p.o., QD	0	0
Favipiravir (58, 59)	31–67†	Purine nucleic acid analogue	150, p.o., BID	100	0
			300, p.o., BID	100	0
FGI-106 (60)	0.1†	Antiviral	2, i.p., QD	100	10
			5, i.p., QD	100	10
Galidesivir (61)	3.1†	Nucleoside analog	25, i.m., BID	100‡	0
GS-5734 (7)	1.5†	Nucleoside analog	10 (day 0) and 3 (day 3), i.p.	100‡	0
			10, i.v., QD	100‡	0
NSC 62914 (62)	5.2†	Antioxidant	2, i.p., QD	90	0
Prochlorperazine (10)	11†, 1.9*	Phenothiazine antipsychotic	10, i.p., QD	10	20
Tetrandrine (9)	0.055†	Two-pore channel blocker	30, i.p., QD (days 0, 1, 3, 5, 7)	70	0
			30, i.p., QD (days 1, 3, 5, 7)	30	0
			90, i.p., QD (days 1, 3, 5, 7)	40	0
Tilorone	0.23†	Antiviral	25, i.p., QD	90	10
			50, i.p., QD	90	10
			30, i.p., QD	100	10
			60, i.p., QD	100	10

^aSymbols: †, replication; *, entry; ‡, nonhuman primate.

^bBID, twice a day; QD, once daily; i.m., intramuscular; p.o., per os; i.v., intravenous; i.p., intraperitoneal.